Bellone M - Search Results

1

Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings.

Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M. Ricupito A, et al. Among authors: bellone m. Cancer Res. 2013 Jun 15;73(12):3545-54. doi: 10.1158/0008-5472.CAN-12-2449. Epub 2013 Mar 28. Cancer Res. 2013. PMID: 23539449

2

Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.

Protti MP, Imro MA, Manfredi AA, Consogno G, Heltai S, Arcelloni C, Bellone M, Dellabona P, Casorati G, Rugarli C. Protti MP, et al. Among authors: bellone m. Cancer Res. 1996 Mar 15;56(6):1210-3. Cancer Res. 1996. PMID: 8640799

3

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).

Imro MA, Manici S, Russo V, Consogno G, Bellone M, Rugarli C, Traversari C, Protti MP. Imro MA, et al. Among authors: bellone m. Cancer Res. 1999 May 15;59(10):2287-91. Cancer Res. 1999. PMID: 10344730

4

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P. Moro M, et al. Among authors: bellone m. Cancer Res. 1999 Jun 1;59(11):2650-6. Cancer Res. 1999. PMID: 10363988

5

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.

Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P. Bellone M, et al. J Immunol. 2000 Sep 1;165(5):2651-6. doi: 10.4049/jimmunol.165.5.2651. J Immunol. 2000. PMID: 10946294

6

Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells.

Castiglioni P, Martin-Fontecha A, Milan G, Tomajer V, Magni F, Michaelsson J, Rugarli C, Rosato A, Bellone M. Castiglioni P, et al. Among authors: bellone m. Cancer Res. 2002 Feb 15;62(4):1116-22. Cancer Res. 2002. PMID: 11861391

7

Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.

Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, Bellone M. Camporeale A, et al. Among authors: bellone m. Cancer Res. 2003 Jul 1;63(13):3688-94. Cancer Res. 2003. PMID: 12839960

8

Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.

Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Sacchi A, et al. Among authors: bellone m. Cancer Res. 2004 Oct 1;64(19):7150-5. doi: 10.1158/0008-5472.CAN-04-1445. Cancer Res. 2004. PMID: 15466213

9

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization.

Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M. Degl'Innocenti E, et al. Among authors: bellone m. Eur J Immunol. 2005 Jan;35(1):66-75. doi: 10.1002/eji.200425531. Eur J Immunol. 2005. PMID: 15597325 Free article.

10

The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.

Casati A, Zimmermann VS, Benigni F, Bertilaccio MT, Bellone M, Mondino A. Casati A, et al. Among authors: bellone m. J Immunol. 2005 Mar 15;174(6):3317-25. doi: 10.4049/jimmunol.174.6.3317. J Immunol. 2005. PMID: 15749863

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters